Dive Brief:
- Endologix plans to close a production facility in Milpitas, California, and lay off 31 people at the site.
- The actions, which the vascular disease company disclosed in state employment notices, affect a facility that Endologix acquired in 2021 through its takeover of PQ Bypass.
- Endologix bought PQ as it worked to recover from a 2020 filing for Chapter 11 bankruptcy, taking control of a peripheral arterial disease device that passed the 1,000-patient milestone last year.
Dive Insight:
Endologix filed for bankruptcy after the COVID-19 pandemic exacerbated its existing financial problems. The company exited Chapter 11 proceedings as a private company owned by Deerfield Partners, its largest creditor. Buying PQ gave Endologix the Detour peripheral arterial disease device and a manufacturing facility in Milpitas, California.
The company plans to lay off 31 people at the Milpitas site in May and June as part of the closure of the facility. Various manufacturing and quality roles will be affected. Most of the layoffs will take place on May 6, with two smaller rounds of cuts scheduled for the following weeks.
Endologix operates offices and manufacturing facilities in two other California cities, Irvine and Santa Rosa. The company acquired the Santa Rosa site as part of the $211 million merger it entered into with stent maker TriVascular Technologies in 2015. As of 2020, Endologix manufactured, assembled and packaged most of its commercial products at the facilities in Irvine and Santa Rosa.
Adding PQ’s Detour system to the portfolio diversified Endologix’s business as the company dealt with challenges to its other products. In 2022, the Food and Drug Administration advised healthcare providers to consider alternatives to Endologix’s AFX2 endovascular grafts when treating abdominal aortic aneurysm patients. Endologix received approval to include an updated warning and data on the AFX2 label later in 2022.
The company changed its leadership team last year, hiring John Liddicoat as CEO and appointing Andrew Davis as chief commercial officer. Davis left Endologix and joined Procyrion later in 2025.
